ReviewNaunyn-Schmiedeberg's archives of pharmacology2025
A comprehensive literature review on the effects of saffron and its bioactive components on traumatic brain injury (TBI).
Review in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Promising natural agents in psychopharmacology described by Rhazes in Al-Hawi and Liber Almansoris: a ninth-century paradigm.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Integrative effects of saffron and physical activity on endurance performance, quality of life, cognitive, emotional, and metabolic outcomes in age-related and neurodegenerative diseases.Frontiers in nutrition · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Traumatic brain injury (TBI) is a leading cause of death in accidents, sports, and warfare. Additionally, TBI imposes a significant financial burden on individuals and governments, necessitating substantial financial support. It also severely diminishes the quality of life for patients and their caregivers. TBI is consisted of two distinct phases: the primary and secondary phases. The primary phase consists of numerous events that occur immediately after the injury or concussion but the second phase takes times and include several of responsive cascades that human body express against TBI. After TBI incidence, several cellular and molecular pathways (inflammatory, apoptotic, anti-oxidant) will be dysregulated. Over the years, numerous therapeutic approaches have been implemented to treat this debilitating condition, aiming to alleviate its symptoms and complications, while enhancing patients' quality of life. Consequently, the search for more efficient with less adverse effects therapeutic methods remains a priority. One herbal medication that has recently garnered considerable attention is saffron. Data were collected from Scopus, Google Scholar, PubMed, and Cochrane Library for clinical, in vivo and in vitro studies published in English between 1992 and Jan 2025. Search terms included "TBI" OR "Traumatic brain injury" AND "Saffron" AND "Safranal" AND "Crocin" AND "Crocetin" AND "Kaempferol". The initial search yielded approximately 3,000 manuscripts. After screening and full-text evaluation, as detailed in the search methodology, ten experiments (in-vitro & in-vivo) were ultimately included. Saffron showed to modulate various signaling pathways and cytokines such as NF-kB, NLRP3, Nrf2, HO-1, Bcl2, and Bax, which will lead to the improvement of TBI sign and symptoms and increase the quality of life. It has been demonstrated that this compound could play a multifactorial role in TBI treatment such as reduction in inflammation, apoptosis, and oxidative stress, while modulating microglia activation. The findings suggest that saffron may play a pivotal role in treating TBI and mitigating its complications by regulating various pathophysiological pathways. However, more clinical trials are necessary to evaluate saffron's effectiveness in individuals diagnosed with TBI. Clinical trials should focus on various areas such as saffrons' safety profile, adverse effects, the exact mechanism of action, its' impact on acute and chronic TBI, rehabilitation, and long-term neuroprotection.
Indexed as
Identifiers
39928149What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.